Literature DB >> 1430147

Morphology of demyelination in the human central nervous system.

J J Hauw1, P Delaère, D Seilhean, P Cornu.   

Abstract

The principles of the neuropathological classification of disorders of central nervous system myelin are recalled. They are illustrated by a few selected examples. Dysmyelination is characterized by the production of an abnormal and unstable myelin sheath; it is often associated with hypomyelination (paucity of myelin formation) and is due to metabolic disorders. It is the main process in leukodystrophies. Storage of different lipids (e.g. sulfatides, long-chain fatty acids) or associated pathology of various cell types (in Alexander's disease, for example) are used for classifying these disorders. Biochemical and genetic characterizations are presently ongoing. Demyelination is the destruction of apparently normal myelin. It is often followed by remyelination. Our present knowledge on the neuropathology of multiple sclerosis, the most common demyelinating disease, is summarized. Cell-mediated demyelination affects the myelin sheaths for an obscure reason. The causes of the multifocal and sharply demarcated plaques, and of the fading of the remyelination process at the edge of some plaques, are not clear. A few examples of demyelinating diseases of known etiology and of various mechanisms are given. The similarities between acute disseminated leukoencephalitis and experimental autoimmune encephalitis are stressed. In progressive multifocal leukoencephalopathy, chronic infection of oligodendrocytes by JC virus induces poorly defined areas of demyelination. In AIDS, the pathogenesis of the myelin change is unclear. Macrophages may be responsible. Toxic and vascular disorders provide also good models for the understanding of mechanisms of demyelination.

Entities:  

Mesh:

Year:  1992        PMID: 1430147     DOI: 10.1016/0165-5728(92)90128-8

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  5 in total

1.  A novel PET marker for in vivo quantification of myelination.

Authors:  Chunying Wu; Changning Wang; Daniela C Popescu; Wenxia Zhu; Eduardo A Somoza; Junqing Zhu; Allison G Condie; Christopher A Flask; Robert H Miller; Wendy Macklin; Yanming Wang
Journal:  Bioorg Med Chem       Date:  2010-11-09       Impact factor: 3.641

2.  A myelin-specific contrast agent for magnetic resonance imaging of myelination.

Authors:  Luca Frullano; Changning Wang; Robert H Miller; Yanming Wang
Journal:  J Am Chem Soc       Date:  2011-01-25       Impact factor: 15.419

3.  Myelin imaging compound (MIC) enhanced magnetic resonance imaging of myelination.

Authors:  Luca Frullano; Junqing Zhu; Changning Wang; Chunying Wu; Robert H Miller; Yanming Wang
Journal:  J Med Chem       Date:  2011-12-16       Impact factor: 7.446

4.  Synthesis and characterization of a novel gadolinium-based contrast agent for magnetic resonance imaging of myelination.

Authors:  Luca Frullano; Junqing Zhu; Robert H Miller; Yanming Wang
Journal:  J Med Chem       Date:  2013-02-18       Impact factor: 7.446

5.  In vivo quantification of myelin changes in the vertebrate nervous system.

Authors:  Yanming Wang; Chunying Wu; Andrew V Caprariello; Eduardo Somoza; Wenxia Zhu; Changning Wang; Robert H Miller
Journal:  J Neurosci       Date:  2009-11-18       Impact factor: 6.167

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.